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http:WHAT THIS PAPER ADDS
The use of fenestrated and branched endovascular repair for complex aortic aneurysms is currently limited by
the high unit cost of the custom made devices and the lack of head to head trial evidence of a better outcome
compared with open surgical repair. In addition, there has been no economic evaluation of f/b EVAR in the
treatment of complex aortic aneurysms. The results of this study are a ﬁrst step towards helping clinicians decide
which patients should beneﬁt from these expensive and innovative devices.Objective: To compare 30 day outcomes and costs of fenestrated and branched stent grafts (f/b EVAR) and open
surgery (OSR) for the treatment of complex abdominal aortic aneurysms (AAA) and thoraco-abdominal aortic
aneurysms (TAAA).
Methods: The multicenter prospective registry WINDOW was set up to evaluate f/b EVAR in high risk patients
with para/juxtarenal AAA, and infradiaphragmatic and supradiaphragmatic TAAA. A control group of patients
treated by OSR was extracted from the national hospital discharge database. The primary endpoint was 30 day
mortality. Secondary endpoints included severe complications, length of stay, and costs. Mortality was assessed
by survival analysis and uni/multivariate Cox regression analyses using pre- and post-operative characteristics.
Bootstrap methods were used to estimate the cost-effectiveness of f/b EVAR versus OSR.
Results: Two hundred and sixty eight cases and 1,678 controls were included. There was no difference in 30 day
mortality (6.7% vs. 5.4%, p ¼ 0.40), but costs were higher with f/b EVAR (V38,212 vs. V16,497, p < .001). After
group stratiﬁcation, mortality was similar with both treatments for para/juxtarenal AAA (4.3% vs. 5.8%, p ¼ .26)
and supradiaphragmatic TAAA (11.9% vs. 19.7%, p ¼ .70), and higher with f/b EVAR for infradiaphragmatic TAAA
(11.9% vs. 4.0%, p ¼ .010). Costs were higher with f/b EVAR for para/juxtarenal AAA (V34,425 vs. V14,907,
p < .0001) and infradiaphragmatic TAAA (V37,927 vs. V17,530, p < .0001), but not different for
supradiaphragmatic TAAA (V54,710 vs. V44,163, p ¼ .18).
Conclusion: f/b EVAR does not appear justiﬁed for patients with para/juxtarenal AAA and infradiaphragmatic
TAAA ﬁt for OSR but may be an attractive option for patients with para/juxtarenal AAA not eligible for surgery
and patients with supradiaphragmatic TAAA. Clinical Trial Registration: http://www.clinicaltrials.gov/ct2/show/
NCT01168037; identiﬁer: NCT01168037 (WINDOW registry).
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The beneﬁts of standard endovascular (EVAR) over open
repair (OSR) for infrarenal abdominal aortic aneurysms
(AAA) have been documented both in terms of 30 day
mortality and length of stay (LOS) by randomized controlled
trials (RCT) and meta-analyses.1e9 However, standard stent
grafts are not adapted to complex aortic aneurysms,
including AAAs with short or absent neck and/or involving
visceral arteries, and thoraco-abdominal aneurysms (TAAA).
Fenestrated and branched stent grafts (f/b EVAR), which
190 M. Michel et al.allow revascularization of thoracic, visceral, and renal ar-
teries, have been developed to ﬁll that gap. Initial reports
have demonstrated feasibility and efﬁcacy of this tech-
nique;10e12 however, no head to head trial has ever been
carried out to compare f/b EVAR with OSR. The very high
unit cost of the custom made f/b stent graft also needs to
be considered. While several in trial analyses and models
have compared the cost-effectiveness of EVAR and OSR in
AAA,2,4,7e9 there has not, to the authors’ knowledge, been
an economic evaluation of f/b EVAR in the treatment of
complex aortic aneurysms. The objective of the present
study was to compare outcomes and costs of f/b EVAR with
those of OSR for complex AAA or TAAA.MATERIALS AND METHODS
Study design
WINDOW is a multicenter prospective registry for patients
treated with f/b EVAR, which has been described previ-
ously.13 Only 30 day data are available at this stage. A
control group of patients treated with OSR was extracted
from the national hospital discharge database (Programme
de médicalisation des systèmes d’information) for the years
2010e2012. This database records all acute care hospital
admissions using diagnostic related groups (DRG), along
with other variables such as diagnoses (primary and sec-
ondary, using the 10th edition of the International Classiﬁ-
cation of Diseases [ICD-10]), surgical procedures, and LOS.
Record linkage is performed at national level. In addition, a
probabilistic analysis of the national hospital discharge
database was performed to consolidate the information
available in cases’ case report forms (CRF) and for com-
parison purposes.
The protocol was approved by the institutional review
board of Hôtel Dieu Hospital (Paris), and all cases signed a
written consent to participate in the registry. The French
Data Protection Authority granted access to control data.Study population
Selection criteria of patients with complex AAA or TAAA
treated by f/b EVAR have been described previously.13
Brieﬂy, patients were included if they were considered at
high risk for open surgery and had an AAA >50 mm in men
(45 mm in women), with or without thoracic aortic aneu-
rysm >55 mm (50 mm in women), and with an infrarenal
neck <10 mm in length or aneurysm extending to the su-
prarenal aorta. Patients were divided into three groups
according to type of aneurysm: para/juxtarenal AAA, infra-
diaphragmatic TAAA, and supradiaphragmatic TAAA. Con-
trol participants were extracted by combining primary
diagnosis and procedure codes and were then assigned to
their anatomical groups based on those same criteria (see
Appendix 2, supplementary material). Emergent and
ruptured aneurysms as well as aortic dissections were
excluded from both groups.
Comorbidities at baseline were drawn from the CRF and
the discharge database for cases, and from the dischargedatabase for controls. To reduce discrepancies caused by
the different recording methods, data from the discharge
database were used for both cases and controls when
comparing baseline characteristics between treatment
groups. The Charlson index14 was calculated to assess pa-
tient severity at inclusion. This was preferred to other in-
dexes e including the Medicare score15 e because it could
be scored using hospital discharge data and has been vali-
dated for use with a claims database, including the French
hospital discharge database.16,17
Study endpoints
The primary clinical endpoint was 30 day all cause mortality.
Secondary endpoints included major complications
(myocardial infarction, stroke, permanent hemodialysis,
major amputation, paraplegia, and bowel infarction) as well
as vascular repeat interventions, LOS (both in hospital and
in the intensive care unit), re-admissions within 30 days
(identiﬁed using record linkage and each patient’s national
anonymized identiﬁcation number), and costs. Endpoints
were recorded in the CRF and checked against the discharge
database for cases and retrieved from the discharge data-
base for controls.
Economic evaluation
Only hospital (acute) resources were considered. Procedure
costs for f/b EVAR were obtained with a bottom up micro-
costing approach that identiﬁed all relevant cost compo-
nents of the procedure and valued each of those compo-
nents for all individual patients18 using the following
variables: duration of the procedure, staff present, medical
devices used, and type of operating theatre. Graft compo-
nents and other supplies for each patient were recorded in
the CRF or retrieved from the surgical ward databases. The
prices of the medical devices used during the procedure
were obtained from each center and are in 2012V (Ap-
pendix 3, supplementary material). Hospitalization costs
were estimated by adjusting the 2012 average national cost
of each patient’s DRG with their actual LOS and resources
used during their hospitalization (intensive care, blood
transfusion, hemodialysis, etc.). This average cost was
drawn from the national hospital cost study, which is un-
dertaken yearly by the Ministry of Health and records actual
costs for all patients admitted to a sample of hospitals
based on a combination of itemized resources and activity
based costing. This allowed exclusion of items relative to
surgery from patients’ hospital costs so as to not count this
twice.
For controls, procedure costs were not estimated with a
micro-costing as there was no access to individual patients
and therefore this could not be performed. Those costs are
included in controls’ hospital costs, which e like cases e
were taken from the national hospital cost study and
adjusted with LOS and other resources used to ensure
comparability between the two groups. No tariffs were
used at any point in the cost computation as this is not
recommended.
Cost-effectiveness of f/b EVAR at 30 days 191Finally, transfers to another acute care hospital and repeat
admissions within 30 days of the initial intervention were also
included in cost computations using the same methodology.
A cost-effectiveness analysis was conducted to assess
incremental costs per incremental death averted with f/b
EVAR versus OSR.Table 1. Patient characteristics at baseline, using data from the
national discharge database for both cases and controls.
f/b EVAR
(n ¼ 268a)
OSR
(n ¼ 1,678)
pb
Age, y, mean (SD) 71.6 (8.5) 69.2 (8.9) <.001
Men, n (%) 250 (93.3) 1,539 (91.7) .38
Type of aneurysm, n (%)
Para/juxtarenal AAA 184 (68.6) 1,382 (82.4) <.001
Infradiaphragmatic TAAA 42 (15.7) 225 (13.4)
Supradiaphragmatic TAAA 42 (15.7) 71 (4.2)
Comorbidities, n (%)
Hypertension 161 (61.5) 858 (51.1) .002
Hyperlipidemia 111 (42.4) 579 (34.5) .013
Diabetes 38 (14.5) 210 (12.5) .37
Coronary artery
occlusive disease
24 (9.2) 138 (8.2) .61
History of stroke 7 (2.7) 35 (2.1) .54
Peripheral arterial
occlusive disease
21 (8.0) 243 (14.5) .005
Cardiac insufﬁciency 19 (7.3) 53 (3.2) .001
Arrhythmia 19 (7.3) 139 (8.3) .57
Chronic pulmonary disease 61 (23.3) 241 (14.4) <.001
Chronic renal disease 23 (8.8) 104 (6.2) .12
Charlson index, n (%)c
0 115 (43.9) 751 (44.8) .22
1 60 (22.9) 461 (27.5)
2 47 (17.9) 249 (14.8)Statistical analysis
The primary goal of the study was to test the null hypoth-
esis that 30 day survival was identical with f/b EVAR and
OSR. Proposed sample sizes of 200 (f/b EVAR) and 600
(OSR), with a total number of required events of 20 and a
0.05 level two sided log-rank test for equality of survival
curves, had 95% power to detect the difference between
the OSR group proportion at time t of 0.900 and the
fenestrated stent grafts group proportion at time t of 0.970
(hazard ratio of 3.459).
Analyses were performed for the entire population and
for the three prospectively deﬁned groups. Dichotomous
variables were compared using the chi-square test or the
Fisher exact test while continuous variables, described by
mean and standard deviation (SD), were assessed with a
Student t test. KaplaneMeier survival analyses were carried
out and the log-rank test was calculated. Univariate and
multivariate analyses were also performed on 30 day
mortality using a Cox model. Variables were included in the
multivariate model if they were signiﬁcant in the univariate
analysis (p < .2). The ﬁnal model was identiﬁed using a
descending stepwise method with a 0.05 signiﬁcance level.
Age, sex, group, and Charlson index were forced. Hazard
ratios (HR) and their 95% conﬁdence intervals (95% CI) were
calculated. Multiple sensitivity analyses were performed to
test the model (presented in Appendix 4, supplementary
material, along with their results).
A concordance analysis using the Kappa test was per-
formed to compare the data present in the CRF and in the
national discharge database for cases. Finally, bootstrap
methods were used to examine the distribution of the in-
cremental cost and incremental effectiveness across the
cost-effectiveness plane for the three subgroups.
Analyses were performed using Excel (2010, Microsoft)
and SAS (9.3, SAS corp. NC) software.3 21 (8.0) 136 (8.1)
4 11 (4.2) 56 (3.3)
 5 8 (3.1) 25 (1.5)
Missing 6 (2.2) 0 (0.0)
y ¼ years.
a n ¼ 262 for comorbidities (six patients could not be found in the
discharge database).
b Chi-square test for dichotomous variables and Student t test for
continuous variables.
c Charlson index: includes myocardial infarction, congestive heart
failure, peripheral vascular disease, cerebrovascular disease, de-
mentia, chronic pulmonary disease, rheumatologic disease, peptic
ulcer disease, mild liver disease, diabetes without chronic com-
plications, diabetes with chronic complications, hemiplegia or
paraplegia, renal disease, any malignancy, moderate or severe liver
disease, metastatic solid tumor, HIV/AIDS.14RESULTS
Patient characteristics
Three hundred and twenty ﬁve patients were assessed for
eligibility for the WINDOW registry. There were 10 deaths
before intervention: rupture while waiting for the custom
made device in four patients, other causes in ﬁve, unknown
in one. They were excluded from the ﬁnal analysis, which
included 268 patients effectively treated by f/b EVAR as it
was not possible to identify controls who had similarly died
before their scheduled surgery. Control participants treated
with OSR (1,678) were collected from the national discharge
database during the same period of time. Cases were
signiﬁcantly older than controls: 71.6 (8.5) versus 69.2 (8.9)years (p < .001). There was no difference in Charlson index,
but all comorbidities were more frequent in cases when
comparing CRF with the national discharge database.
However, when the national discharge database was used
for both cases and controls, only dyslipidemia, hyperten-
sion, chronic pulmonary disease, and congestive heart fail-
ure were signiﬁcantly more common in f/b EVAR cases,
while peripheral arterial occlusive disease was more com-
mon in controls (Table 1). On average 6.2 (2.4) devices were
implanted in patients treated by f/b EVAR.Costs
The costs of the initial hospitalization were estimated at
V37,708 (23,196) on average for a patient treated with f/b
EVAR vs. V16,255 (16,660) for a patient treated with OSR
(p < .001). The cost of medical devices used in f/b EVAR
Table 3. Multivariate Cox regression analysis (ﬁnal modela).
Hazard
ratio
95% conﬁdence
interval
p
Mean age at intervention 1.06 1.04e1.09 <.001
Sex
Male 1 e .61
Female 1.19 0.61e2.30
Treatment
OSR 1 e .92
f/b EVAR 0.97 0.57e1.66
Type of aneurysm
Para/juxtarenal AAA 1 e <.001
Infradiaphragmatic TAAA 0.82 0.47e1.44
Supradiaphragmatic TAAA 2.80 1.62e4.84
Charlson index
0 1 e .60
1 0.86 0.54e1.37
2 1.04 0.60e1.78
3 1.13 0.63e2.04
4 0.18 0.02e1.35
 5 0.91 0.31e2.64
Complications
Myocardial infarction 5.52 2.36e12.9 <.001
Severe ischemic colitis
and bowel infarction
5.39 3.16e9.21 <.001
Permanent hemodialysis 2.16 1.40e3.34 <.001
Re-intervention 2.28 1.43e3.64 <.001
a Variables were included in the multivariate model if they were
under the 0.2 signiﬁcance level of the univariate analysis. The
variables in the ﬁnal model were identiﬁed using a descending
stepwise method with a 0.05 signiﬁcance level. Age, sex, group
(¼type of aneurysm), and Charlson index were forced.
192 M. Michel et al.accounted for the difference, as it amounted to V21,905
(3,337). There was no difference in readmission costs:
V5,985 (5,969) for f/b EVAR cases vs. V4,570 (4,886) for
controls, p ¼ .248. Total costs at 30 days (or at patient
discharge) were V38,212 (23,252) per case and V16,497
(16,695) per control (p < .001).
While costs were signiﬁcantly higher for cases in para/
juxtarenal AAA and infradiaphragmatic TAAA, there was no
signiﬁcant difference in costs between f/b EVAR and OSR in
supradiaphragmatic TAAA (Table 2). Overall, patients with
supradiaphragmatic TAAA had higher costs than patients
with para/juxtarenal AAA and infradiaphragmatic TAAA in
both treatment groups.
Mortality
At 30 days, 18 patients treated with f/b EVAR (6.7%) and 90
patients treated with OSR (5.4%) had died (p ¼ .40).
KaplaneMeier survival analysis at 30 days found no differ-
ence in survival rates between cases and controls (93.3% vs.
94.6%, p ¼ .48). There was no difference in survival for
patients with para/juxtarenal AAA (95.7% vs. 94.2%,
p ¼ .26) and supradiaphragmatic TAAA (88.1% vs. 79.6%,
p ¼ .70), while cases with infradiaphragmatic TAAA had a
worse survival than controls (88.1% vs. 95.0%, p ¼ .010).
Univariate Cox regression analysis found a signiﬁcant
association between 30 day mortality and age, type of
aneurysm, and all complications except amputations.
Multivariate analysis conﬁrmed the absence of a signiﬁcant
impact of treatment on 30 day mortality (HR 0.97, 95% CI
0.57e1.66) and a signiﬁcant association with age, type of
aneurysm, and some of the complications (Table 3, sensi-
tivity analyses in Appendix 4, supplementary material).
Economic evaluation
f/b EVAR had a higher cost than OSR for a similar clinical
outcome and was therefore dominated. The bootstrap
analysis per group (Fig. 1) showed little uncertainty sur-
rounding this result in para/juxtarenal AAA and infradiaph-
ragmatic TAAA, with f/b EVAR being less effective in patientsTable 2. Hospitalization costs per type of aneurysm (in 2012 V).
f/b EVAR
Mean (SD) pa
Initial hospitalization
Para/juxtarenal AAA 33,919 (21,906) <.001
Infradiaphragmatic TAAA 37,517 (11,981)
Supradiaphragmatic TAAA 54,121 (29,069)
30 day re-admissions
Para/juxtarenal AAA 5,686 (6,856) .794
Infradiaphragmatic TAAA 5,327 (2,943)
Supradiaphragmatic TAAA 8,237 (1,968)
Total costs at 30 daysc
Para/juxtarenal AAA 34,425 (22,021) <.001
Infradiaphragmatic TAAA 37,927 (11,994)
Supradiaphragmatic TAAA 54,710 (28,919)
a ANOVA test.
b Student t test.
c Or at patient’s discharge.with infradiaphragmatic TAAA. Only supradiaphragmatic
TAAA could potentially beneﬁt from f/b EVAR and be cost-
effective; however, high uncertainty surrounded this result.Complications
Based on data recorded in the CRF, permanent hemodial-
ysis was more frequent after OSR (5.6% vs. 20.8%, p < .001)
and spinal cord ischemia was more frequent after f/b EVAROSR f/b EVAR vs. OSR
Mean (SD) pa pb
14,661 (12,822) <.001 <.0001
17,239 (12,873) <.0001
44,158 (45,089) .2026
4,487 (4,831) .566 .4064
5,444 (5,416) .9723
337 () .0737
14,907 (12,889) <.001 <.0001
17,530 (12,953) <.0001
44,163 (45,090) .1771
Figure 1. Bootstrap methods assessing the cost-effectiveness of f/b EVAR versus OSR in each group. Green, para/juxtarenal abdominal
aortic aneurysm; red, infradiaphragmatic thoraco-abdominal aortic aneurysm; blue, supradiaphragmatic thoraco-abdominal aortic
aneurysm.
Cost-effectiveness of f/b EVAR at 30 days 193(4.1% vs. 1.0%, p < .001). However, 63.6% of patients
treated with f/b EVAR recovered, leading to a low rate of
permanent paraplegia (1.5%) (Table 4). Using the national
discharge database for both f/b EVAR cases and controls,
however, led to different results: whereas spinal cord
ischemia was still more frequent after f/b EVAR, patients
treated with f/b EVAR also presented more myocardial in-
farctions (3.1% vs. 1.2%, p ¼ .019), strokes (4.2% vs. 0.7%,
p < .001), and re-interventions (15.3% vs. 10.3%, p ¼ .017),
while there was no difference in the occurrence of renal
failure (13.4% vs. 17.2%, p ¼ .120). Appendix 5
(supplementary material) compares the rate of complica-
tions per type of aneurysm using both data sources, and
Appendix 6 (supplementary material) shows the concor-
dance analysis of the two sources.Table 4. Post-operative complications, n (%).
Complications Using CRF for cases
discharge database f
f/b EVAR
(n ¼ 268)
OSR
(n ¼
Major amputation 1 (0.4) 4 (0.2
Myocardial infarction 4 (1.5) 20 (1
Stroke 5 (1.9) 12 (0
Paraplegia 11 (4.1) 16 (1
Incl. permanent paraplegia 4 (1.5)
Mechanical ventilation  7 days 14 (5.2) 124 (
Severe ischemic colitis and bowel infarction 6 (2.2) 51 (3
Permanent hemodialysis 15 (5.6) 289 (
Re-intervention 34 (12.7) 173 (
a Chi-square test (or the Fisher exact test depending on the number oLength of stay and 30 day readmissions
Total initial LOS (including transfers to another acute care
hospital) was 13.9 (15.6) days for f/b EVAR patients and
16.2 (14.3) days for OSR patients (p ¼ .020). There was no
difference in LOS in ICU: 3.6 (13.5) days after f/b EVAR vs.
4.0 (10.2) after OSR (p ¼ .55). A signiﬁcant positive asso-
ciation was found between type of aneurysm and LOS (total
and in ICU) in both f/b EVAR cases and controls, and a
signiﬁcantly higher total LOS for controls versus f/b EVAR
cases in patients with para/juxtarenal AAA and infradiaph-
ragmatic TAAA. More f/b EVAR cases than controls were re-
admitted within 30 days of the intervention (9.1% vs. 5.6%,
p ¼ .035), although there was no difference in their LOS
(total or ICU). After excluding hemodialysis sessions, it was
found that there were more re-admissions for a circulatoryand national
or controls
Using national discharge database
for cases and controls
1,678)
pa f/b EVAR
(n ¼ 262)
OSR
(n ¼ 1,678)
pa
) .69 1 (0.4) 4 (0.2) .67
.2) .68 8 (3.1) 20 (1.2) .019
.7) .060 11 (4.2) 12 (0.7) <.001
.0) <.001 8 (3.1) 16 (1.0) .004
NA NA NA NA NA
7.4) .20 18 (6.9) 124 (7.4) .76
.0) .47 7 (2.8) 51 (3.0) .75
17.2) <.001 35 (13.4) 289 (17.2) .120
10.3) .24 40 (15.3) 173 (10.3) .017
f observations).
194 M. Michel et al.system disease in the f/b EVAR group (44.0% vs. 15.7%) and
more readmissions for a respiratory system disease in the
OSR group (13.3% vs. 0%). In addition, more controls than
cases were transferred to a long-term care or rehabilitation
facility at discharge (5.0% vs. 15.4%, p < .001). This was also
true for patients with para/juxtarenal AAA (2.2% vs. 15.8%,
p < .001); however, there was no difference for patients
with infra- or supradiaphragmatic TAAA.DISCUSSION
The results of this study suggest that f/b EVAR is not a cost-
effective option for para/juxtarenal AAA or infradiaph-
ragmatic TAAA. Therefore, OSR should be preferred when-
ever patients are eligible, although f/b EVAR may be a
valuable treatment in high risk patients with para/juxtarenal
aneurysms, with a mortality rate close to the mortality of
OSR in low risk patients. For infradiaphragmatic TAAA, the
poorer results of f/b EVAR may be explained by several
factors, including a higher risk for surgery, technical issues
related to anatomy, and the need for four fenestrations
which increases the complexity of the procedure. For
supradiaphragmatic TAAA, no difference was found in
mortality and costs between f/b EVAR and OSR, suggesting
that f/b EVAR may become a preferred option even in low
risk patients, but the study was not sufﬁciently powered to
make a stronger case for those patients.
The efﬁcacy of infrarenal EVAR has been evaluated in
several comparative studies, which have found a relatively
low mortality e between 1.1% and 1.8%.3,4,6,19 Repair of
complex aortic aneurysms presents a bigger challenge. For
such aneurysms, no study has compared f/b EVAR and OSR in
a head to head trial, although a recent retrospective com-
parison of 30 day outcomes suggests that f/b EVAR is asso-
ciatedwith reduced 30 daymortality andmorbidity compared
with OSR.20 However, this study concerned only “eligible high
volume hospitals,” and the deﬁnition of complex aortic
aneurysm was limited to involvement of visceral arteries.
Moreover, comparison with results of the present study is
rendered difﬁcult by the lack of data on morphologic char-
acteristics of the AAA and differences in case mix and co-
morbid conditions. Cohort studies12,21 also reported a slightly
lower mortality than the present study (4.1% and 5.7% 30 day
mortality vs. 6.7%), but the present study included a higher
proportion of more risky extensive aneurysms.
LOS was shorter in patients treated by f/b EVAR (13.9 vs.
16.2 days, p ¼ .020), as is also the case in studies comparing
EVAR and OSR for infrarenal AAA. The LOS in the present
study is higher than that reported in the literature e be-
tween 3.7 and 12.0 days after f/b EVAR,7,22e25 and between
9.9 and 16.1 days after OSR.7,9,26,27 LOS in ICU was also
higher (3e4 days vs. only 1 day in the literature). The dif-
ference may be because, in this study, transfers to other
acute care institutions were included in the LOS calculation.
Excluding transfers resulted in a LOS of 12.3 days for f/b
EVAR and 15.2 days for OSR, which is within the range re-
ported in the literature, albeit not that of the more recent
American College of Surgeons registry.20Finally, f/b EVAR was predictably more costly than EVAR
because of the cost of custom made stent grafts. The OSR
cost in the present study was lower than previously re-
ported, with the usual costs ranging from V18,242 to
V27,930 2,4,9 and up to V39,345,7 compared with V16,255
in the present study. This may be a result of differences in
DRG cost calculations. To the authors’ knowledge, the cost
of f/b EVAR treatment has been assessed only once, by the
Ontario Health Technology Advisory Committee,28 which
found a cost of V27,747 for the initial hospitalization
(V10,000 less than ﬁgures in the present study). This dif-
ference may be explained by the shorter LOS (6 days on
average after f/b EVAR vs. close to 14 days in the present
study), as the cost of the devices was similar in Canada and
France (V20,317 vs. V21,905).
There are some limitations to the present ﬁndings. The
study is not a traditional head to head RCT; as a result,
patients undergoing f/b EVAR were on average 2 years
older and sicker than those undergoing OSR. The present
risk adjustment used age and Charlson index but other
comorbidities may not be accounted for. A RCT was not
chosen for several reasons: (1) the relatively low number of
patients, even at a nationwide level, that would meet its
inclusion criteria; (2) discrepancies between the number of
centers currently performing OSR for complex AAA and
TAAA and the low number of centers having already ful-
ﬁlled the learning curve for f/b EVAR; (3) difﬁculties to
convince patients to enter a protocol aimed at comparing a
very invasive technique to a lighter one. The weakness of
this choice is that clinical outcomes and costs were not
measured in an identical way in both arms, the f/b EVAR
cases’ CRF being more thorough and complete than the
controls’ data present in the national discharge database.
The discrepancies between the two data sources can be
observed in the poor results of the concordance analysis,
especially where comorbidities are concerned. It also ex-
plains the differences between what is reported here vs.
what is present in the earlier article by Marzelle et al.,13 as
the latter reported CRF data while we mainly used the
national discharge database. Although researchers are
increasingly using discharge databases worldwide, these
usually are not designed for research purposes. As such,
the data available for a given patient are subject to coding
incentives and more likely to contain comorbidities and
complications that impact on reimbursement. In addition,
using two different data sources meant only variables that
were recorded in both could be included. As a result body
mass index or aneurysm diameter could not be included in
analyses despite potentially inﬂuencing mortality. Also, a
nationwide database was compared with only eight cen-
ters performing f/b EVAR, but while a comparison limited
to the same centers may appear more robust, it proved
impossible to do because f/b EVAR centers had switched
massively to endovascular repair and could not provide a
sufﬁciently large control group. Finally, the discharge
database records only hospital deaths, therefore mortality
in the control arm may have been underestimated as
deaths occurring at home or in another type of institution
Cost-effectiveness of f/b EVAR at 30 days 195were not recorded, although the concordance was high
and mortality rate for OSR was close to that reported in
EVAR vs. OSR trials: 5.4% in the present study vs. 4.3e4.7%
in others3,4,6 and up to 10% in TAAA.29 This suggests that
using the discharge database had only a limited impact on
the 30 day mortality evaluation.
Endovascular technology is a rapidly evolving ﬁeld. Since
the start of the current study, new devices from different
companies have been developed, which will probably
decrease the cost of the stent grafts and reduce the waiting
time for patients (and thus the risk of rupture).30 Parallel
grafts such as chimney grafts using a combination of a
standard stent graft with standard covered stents are also
being developed, with the advantages of being readily
applicable and much cheaper.31
CONCLUSION
f/b EVAR does not appear to be justiﬁed for patients with
para/juxtarenal AAA and infradiaphragmatic TAAA ﬁt for
OSR. However, it offers an attractive option for patients
with para/juxtarenal AAA at high risk for surgery and for
patients with supradiaphragmatic TAAA, including patients
ﬁt for open surgery. Durability of these devices needs to be
assessed by longer-term follow up.
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